Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Arvaya Healthcare's yield on cost for the quarter that ended in Jun. 2026 was 0.00.
The historical rank and industry rank for Arvaya Healthcare's 5-Year Yield-on-Cost % or its related term are showing as below:
BOM:524723's 5-Year Yield-on-Cost % is not ranked *
in the Medical Distribution industry.
Industry Median: 3.17 * Ranked among companies with meaningful 5-Year Yield-on-Cost % only.
Of course the risk here is that the company may not raise its dividends as it did before. The key is to select the companies that can consistently raise its dividends. Usually companies with long history of raising dividends tend to do so.
Arvaya Healthcare 5-Year Yield-on-Cost % Related Terms
BOM:524723 vs MCK, COR, CAH: 5-Year Yield-on-Cost % Comparison
For the Medical Distribution subindustry, Arvaya Healthcare's 5-Year Yield-on-Cost %, along with its competitors' market caps and 5-Year Yield-on-Cost % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Arvaya Healthcare 5-Year Yield-on-Cost % vs Medical Distribution Industry
For the Medical Distribution industry and Healthcare sector, Arvaya Healthcare's 5-Year Yield-on-Cost % distribution charts can be found below:
* The bar in red indicates where Arvaya Healthcare's 5-Year Yield-on-Cost % falls into.
Dividend Yield % and dividend growth of a stock is an important factor for income investors. But if company A raises its dividend constantly faster than company B, company A's future dividend yield might be much higher than Company B's even if their yields are the same now and their stock prices do not change.
Yield on Cost assumes that you buy and the stock today, and hold it for 5 years. If the company raises it dividends at the same rate as it did over the past 5 years, the dividends investors receive annually in 5 years relative to the stock price today.
Arvaya Healthcare (BOM:524723) has a 5-Year Yield-on-Cost % of 0.00 as of Sep. 13, 2026. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Arvaya Healthcare and its competitors. According to the industry distribution chart, Arvaya Healthcare ranks #999999 out of 71 companies in the Medical Distribution industry.
Is Arvaya Healthcare's 5-Year Yield-on-Cost % too high?
Arvaya Healthcare's current 5-Year Yield-on-Cost % is 0.00. Based on the distribution chart, Arvaya Healthcare ranks #999999 out of 71 companies in the Medical Distribution industry, which is in the bottom quartile relative to peers. Overall, Arvaya Healthcare has a GF Score™ of 57/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Arvaya Healthcare's 5-Year Yield-on-Cost % compare to MCK and COR?
According to the Medical Distribution industry distribution chart, Arvaya Healthcare ranks #999999 out of 71 companies for 5-Year Yield-on-Cost %. This places Arvaya Healthcare in the lower half of its industry. The industry median 5-Year Yield-on-Cost % is 3.17. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 5-Year Yield-on-Cost % for a Medical Distribution company?
The median 5-Year Yield-on-Cost % among Medical Distribution companies is 3.17, based on 71 companies in the industry. Companies in the top quartile (top 25%) have a 5-Year Yield-on-Cost % significantly above this median, while those in the bottom quartile fall well below. However, 5-Year Yield-on-Cost % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 5-Year Yield-on-Cost % mean?
A high 5-Year Yield-on-Cost % can signal that a stock is expensive relative to its fundamentals. 5-Year Yield on Cost measures the expected yield based on a company's current yield and 5-year dividend growth. View historical data on Arvaya Healthcare and its competitors. For the Medical Distribution industry, the median 5-Year Yield-on-Cost % is 3.17 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Arvaya Healthcare's current 5-Year Yield-on-Cost % is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arvaya Healthcare stock overvalued right now?
Based on GuruFocus' analysis, Arvaya Healthcare (BOM:524723) is currently considered Possible Value Trap. The stock's GF Value™ is ₹201.65, compared to a current price of ₹122.00 — trading 39.5% below its estimated fair value. The current 5-Year Yield-on-Cost % is 0.00. Arvaya Healthcare's overall GF Score™ is 57/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 5-Year Yield-on-Cost % calculated?
5-Year Yield-on-Cost % is calculated from a company's financial statements. For Arvaya Healthcare (BOM:524723), the current 5-Year Yield-on-Cost % is 0.00 as of Sep. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Arvaya Healthcare (BOM:524723) Overvalued in 2026?
Based on GuruFocus' analysis, Arvaya Healthcare stock appears to be undervalued.
The current stock price of ₹122.00 is trading 39.5% below its estimated GF Value™ of ₹201.65.
GuruFocus considers Arvaya Healthcare to be Possible Value Trap.
Key valuation signals for BOM:524723:
5-Year Yield-on-Cost %: 0.00
GF Value™: ₹201.65 vs. price of ₹122.00 (39.5% below fair value)
No single metric tells the full story. See the BOM:524723 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Arvaya Healthcare Ltd is focused on developing an integrated healthcare platform in India that combines hospital services, diagnostics, wellness services, and digital health management solutions. Its operations include multi-specialty hospitals, a digital health platform for appointment booking and health record management, diagnostic services including laboratory testing and home sample collection, and wellness facilities offering preventive and recovery-focused programs.
57GF Score
Get the complete analysis for BOM:524723
5-Year Yield-on-Cost % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:524723 has been successfully added to your 
